Supplementary Material for: Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia

Here, we present a novel case of a patient with chronic lymphocytic leukemia (CLL) who received CTLA-4 and then PD-1 immune-checkpoint blockade (ICB) as treatment for concomitant metastatic melanoma. Whereas the metastatic melanoma was responsive to ICB, the CLL rapidly progressed (but responded to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: M., Burgess, C., Keane, J.W.D., Tobin, S.C., Law, A., Griffin, D., Gill, A.D., Ewing, V., Atkinson, P., Mollee, M.B., Sabdia, N.A., Saunders, M.K., Gandhi
Format: Dataset
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator M., Burgess
C., Keane
J.W.D., Tobin
S.C., Law
A., Griffin
D., Gill
A.D., Ewing
V., Atkinson
P., Mollee
M.B., Sabdia
N.A., Saunders
M.K., Gandhi
description Here, we present a novel case of a patient with chronic lymphocytic leukemia (CLL) who received CTLA-4 and then PD-1 immune-checkpoint blockade (ICB) as treatment for concomitant metastatic melanoma. Whereas the metastatic melanoma was responsive to ICB, the CLL rapidly progressed (but responded to ICB cessation and ibrutinib). There were no new genetic mutational drivers to explain the altered clinical course. PD-1/PD-L1/PD-L2 and CTLA-4/CD80/CD86 expression was not increased in CLL B cells, CD8+ or CD4+ T-cell subsets, or monocytes. The patient’s CLL B cells demonstrated strikingly prolonged in vitro survival during PD-1 blockade, which was not observed in samples taken before or after ICB, or with other patients. To our knowledge, a discordant clinical course to ICB coupled with these biological features has not been reported in a patient with dual malignancies.
doi_str_mv 10.6084/m9.figshare.21629564
format Dataset
fullrecord <record><control><sourceid>datacite_PQ8</sourceid><recordid>TN_cdi_datacite_primary_10_6084_m9_figshare_21629564</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_6084_m9_figshare_21629564</sourcerecordid><originalsourceid>FETCH-LOGICAL-d914-d5376f810992af7bd47db0f8380bf353bc08c584948e93f87c65060ab0723c1d3</originalsourceid><addsrcrecordid>eNo1kL1ugzAUhVk6VGnfoINfgNRgA3a3lv5KiVol2dHFvg5WMEbGDHmbPmpTJZnOGc75hi9JHjK6LKngj04ujd1PHQRc5lmZy6Lkt8nvdh7HHh0OEcKRrCFisNAT48MT2eDk-zlaPxBvyBp7GLwDEj35CX4fwDnU5BUhdmlGXnqvDqCRtHMkW-vmPsKAfp7IBkarzxecpgut9oPyzp42kdRd8INVZHV0Y-fVMf53nA_oLNwlNwb6Ce8vuUh272-7-jNdfX981c-rVMuMp7pgVWlERqXMwVSt5pVuqRFM0NawgrWKClUILrlAyYyoVFnQkkJLq5ypTLNFws9YDRGUjdiMwbqTkiajzb-_xsnm6q-5-mN_U6Zv7Q</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>dataset</recordtype></control><display><type>dataset</type><title>Supplementary Material for: Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia</title><source>DataCite</source><creator>M., Burgess ; C., Keane ; J.W.D., Tobin ; S.C., Law ; A., Griffin ; D., Gill ; A.D., Ewing ; V., Atkinson ; P., Mollee ; M.B., Sabdia ; N.A., Saunders ; M.K., Gandhi</creator><creatorcontrib>M., Burgess ; C., Keane ; J.W.D., Tobin ; S.C., Law ; A., Griffin ; D., Gill ; A.D., Ewing ; V., Atkinson ; P., Mollee ; M.B., Sabdia ; N.A., Saunders ; M.K., Gandhi</creatorcontrib><description>Here, we present a novel case of a patient with chronic lymphocytic leukemia (CLL) who received CTLA-4 and then PD-1 immune-checkpoint blockade (ICB) as treatment for concomitant metastatic melanoma. Whereas the metastatic melanoma was responsive to ICB, the CLL rapidly progressed (but responded to ICB cessation and ibrutinib). There were no new genetic mutational drivers to explain the altered clinical course. PD-1/PD-L1/PD-L2 and CTLA-4/CD80/CD86 expression was not increased in CLL B cells, CD8+ or CD4+ T-cell subsets, or monocytes. The patient’s CLL B cells demonstrated strikingly prolonged in vitro survival during PD-1 blockade, which was not observed in samples taken before or after ICB, or with other patients. To our knowledge, a discordant clinical course to ICB coupled with these biological features has not been reported in a patient with dual malignancies.</description><identifier>DOI: 10.6084/m9.figshare.21629564</identifier><language>eng</language><publisher>Karger Publishers</publisher><subject>Medicine</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>780,1894</link.rule.ids><linktorsrc>$$Uhttps://commons.datacite.org/doi.org/10.6084/m9.figshare.21629564$$EView_record_in_DataCite.org$$FView_record_in_$$GDataCite.org$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>M., Burgess</creatorcontrib><creatorcontrib>C., Keane</creatorcontrib><creatorcontrib>J.W.D., Tobin</creatorcontrib><creatorcontrib>S.C., Law</creatorcontrib><creatorcontrib>A., Griffin</creatorcontrib><creatorcontrib>D., Gill</creatorcontrib><creatorcontrib>A.D., Ewing</creatorcontrib><creatorcontrib>V., Atkinson</creatorcontrib><creatorcontrib>P., Mollee</creatorcontrib><creatorcontrib>M.B., Sabdia</creatorcontrib><creatorcontrib>N.A., Saunders</creatorcontrib><creatorcontrib>M.K., Gandhi</creatorcontrib><title>Supplementary Material for: Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia</title><description>Here, we present a novel case of a patient with chronic lymphocytic leukemia (CLL) who received CTLA-4 and then PD-1 immune-checkpoint blockade (ICB) as treatment for concomitant metastatic melanoma. Whereas the metastatic melanoma was responsive to ICB, the CLL rapidly progressed (but responded to ICB cessation and ibrutinib). There were no new genetic mutational drivers to explain the altered clinical course. PD-1/PD-L1/PD-L2 and CTLA-4/CD80/CD86 expression was not increased in CLL B cells, CD8+ or CD4+ T-cell subsets, or monocytes. The patient’s CLL B cells demonstrated strikingly prolonged in vitro survival during PD-1 blockade, which was not observed in samples taken before or after ICB, or with other patients. To our knowledge, a discordant clinical course to ICB coupled with these biological features has not been reported in a patient with dual malignancies.</description><subject>Medicine</subject><fulltext>true</fulltext><rsrctype>dataset</rsrctype><creationdate>2022</creationdate><recordtype>dataset</recordtype><sourceid>PQ8</sourceid><recordid>eNo1kL1ugzAUhVk6VGnfoINfgNRgA3a3lv5KiVol2dHFvg5WMEbGDHmbPmpTJZnOGc75hi9JHjK6LKngj04ujd1PHQRc5lmZy6Lkt8nvdh7HHh0OEcKRrCFisNAT48MT2eDk-zlaPxBvyBp7GLwDEj35CX4fwDnU5BUhdmlGXnqvDqCRtHMkW-vmPsKAfp7IBkarzxecpgut9oPyzp42kdRd8INVZHV0Y-fVMf53nA_oLNwlNwb6Ce8vuUh272-7-jNdfX981c-rVMuMp7pgVWlERqXMwVSt5pVuqRFM0NawgrWKClUILrlAyYyoVFnQkkJLq5ypTLNFws9YDRGUjdiMwbqTkiajzb-_xsnm6q-5-mN_U6Zv7Q</recordid><startdate>20221128</startdate><enddate>20221128</enddate><creator>M., Burgess</creator><creator>C., Keane</creator><creator>J.W.D., Tobin</creator><creator>S.C., Law</creator><creator>A., Griffin</creator><creator>D., Gill</creator><creator>A.D., Ewing</creator><creator>V., Atkinson</creator><creator>P., Mollee</creator><creator>M.B., Sabdia</creator><creator>N.A., Saunders</creator><creator>M.K., Gandhi</creator><general>Karger Publishers</general><scope>DYCCY</scope><scope>PQ8</scope></search><sort><creationdate>20221128</creationdate><title>Supplementary Material for: Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia</title><author>M., Burgess ; C., Keane ; J.W.D., Tobin ; S.C., Law ; A., Griffin ; D., Gill ; A.D., Ewing ; V., Atkinson ; P., Mollee ; M.B., Sabdia ; N.A., Saunders ; M.K., Gandhi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d914-d5376f810992af7bd47db0f8380bf353bc08c584948e93f87c65060ab0723c1d3</frbrgroupid><rsrctype>datasets</rsrctype><prefilter>datasets</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Medicine</topic><toplevel>online_resources</toplevel><creatorcontrib>M., Burgess</creatorcontrib><creatorcontrib>C., Keane</creatorcontrib><creatorcontrib>J.W.D., Tobin</creatorcontrib><creatorcontrib>S.C., Law</creatorcontrib><creatorcontrib>A., Griffin</creatorcontrib><creatorcontrib>D., Gill</creatorcontrib><creatorcontrib>A.D., Ewing</creatorcontrib><creatorcontrib>V., Atkinson</creatorcontrib><creatorcontrib>P., Mollee</creatorcontrib><creatorcontrib>M.B., Sabdia</creatorcontrib><creatorcontrib>N.A., Saunders</creatorcontrib><creatorcontrib>M.K., Gandhi</creatorcontrib><collection>DataCite (Open Access)</collection><collection>DataCite</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>M., Burgess</au><au>C., Keane</au><au>J.W.D., Tobin</au><au>S.C., Law</au><au>A., Griffin</au><au>D., Gill</au><au>A.D., Ewing</au><au>V., Atkinson</au><au>P., Mollee</au><au>M.B., Sabdia</au><au>N.A., Saunders</au><au>M.K., Gandhi</au><format>book</format><genre>unknown</genre><ristype>DATA</ristype><title>Supplementary Material for: Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia</title><date>2022-11-28</date><risdate>2022</risdate><abstract>Here, we present a novel case of a patient with chronic lymphocytic leukemia (CLL) who received CTLA-4 and then PD-1 immune-checkpoint blockade (ICB) as treatment for concomitant metastatic melanoma. Whereas the metastatic melanoma was responsive to ICB, the CLL rapidly progressed (but responded to ICB cessation and ibrutinib). There were no new genetic mutational drivers to explain the altered clinical course. PD-1/PD-L1/PD-L2 and CTLA-4/CD80/CD86 expression was not increased in CLL B cells, CD8+ or CD4+ T-cell subsets, or monocytes. The patient’s CLL B cells demonstrated strikingly prolonged in vitro survival during PD-1 blockade, which was not observed in samples taken before or after ICB, or with other patients. To our knowledge, a discordant clinical course to ICB coupled with these biological features has not been reported in a patient with dual malignancies.</abstract><pub>Karger Publishers</pub><doi>10.6084/m9.figshare.21629564</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier DOI: 10.6084/m9.figshare.21629564
ispartof
issn
language eng
recordid cdi_datacite_primary_10_6084_m9_figshare_21629564
source DataCite
subjects Medicine
title Supplementary Material for: Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T04%3A17%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-datacite_PQ8&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.au=M.,%20Burgess&rft.date=2022-11-28&rft_id=info:doi/10.6084/m9.figshare.21629564&rft_dat=%3Cdatacite_PQ8%3E10_6084_m9_figshare_21629564%3C/datacite_PQ8%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true